MiNK Therapeutics Files 8-K on Financials
Ticker: INKT · Form: 8-K · Filed: Nov 14, 2024 · CIK: 1840229
Sentiment: neutral
Topics: financial-reporting, company-update
TL;DR
MiNK Therapeutics dropped an 8-K on financials, check it out.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as AgenTus Therapeutics, Inc. until January 12, 2021, is incorporated in Delaware and headquartered in New York, NY.
Why It Matters
This filing provides investors with an update on MiNK Therapeutics' operational and financial status, including any new financial statements or exhibits.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate material changes or risks.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- November 14, 2024 (date) — Date of earliest event reported
- 149 Fifth Avenue, Suite 500 New York , New York 10010 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details would be within the attached documents.
When was MiNK Therapeutics, Inc. previously known by another name?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc. until January 12, 2021.
Where is MiNK Therapeutics, Inc. headquartered?
The company's principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
What is the Standard Industrial Classification for MiNK Therapeutics, Inc.?
The SIC code is 2836, categorized under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
What is the Commission File Number for MiNK Therapeutics, Inc.?
The Commission File Number is 001-40908.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-11-14 07:00:34
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share INKT The NASDAQ Cap
Filing Documents
- f8k_111424.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 42KB
- 0001171843-24-006360.txt ( ) — 258KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_111424_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 14, 2024, MiNK Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit The following exhibit is furnished herewith: 99.1 Press Release dated November 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: November 14, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin Principal Financial Officer